6-K filed Aug 6, 2026 at 11:08 ET
Genmab reported strong H1 2026 results with revenue up 25% YoY to $2,051M, driven by DARZALEX and Kesimpta royalties and EPKINLY sales. The company raised its full-year 2026 revenue guidance to $4.325-4.525B (from $4.065-4.395B) and adjusted operating profit guidance to $1.065-1.385B (from $0.900-1.400B). Positive Phase 3 data for epcoritamab in DLBCL and progress on Rina-S and petosemtamab support the pipeline, but net profit declined to $356M from $531M due to higher interest expense from the Merus acquisition debt and increased operating costs.